Low-dose Magnesium Sulfate Versus High Dose in the Early Management of Rapid Atrial Fibrillation: Randomized Controlled Double-blind Study (LOMAGHI Study).

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Secondary outcome included resolution time (defined as the elapsed time from start of treatment to therapeutic response), sinus rhythm conversion rate, and adverse events within the first 24 hours.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

The researchers undertook a randomized, controlled, double-blind clinical trial in three university hospital EDs between August 2009 and December 2014.

What Was Measured

The subject headings attached to it are Administration, Intravenous, Anti-Arrhythmia Agents, Atrial Fibrillation, Emergency Service, Hospital and Magnesium Sulfate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Academic emergency medicine : official journal of the Society for Academic Emergency Medicine), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.